Skip to content Skip to footer
Subscribe Now
35th World Congress for Neurorehabilitation New Advances in Neurorehabilitation
EVENTS

35th World Congress for Neurorehabilitation: New Advances in Neurorehabilitation

Conference Series is delighted to welcome you to attend the “35th World Congress for Neurorehabilitation” to be held in Amsterdam, Netherlands, from August 07-08, 2023. The exhilarating scientific program will focus on Clinical Neurology, Cognitive Neuroscience Neurorehabilitation, Neurosurgery, Psychiatry.  The two days program will be filled with insightful presentations, engaging discussions, and networking opportunities. This…
July 7, 2023

Read more

VIEWPOINTS_Brian Ingram_2023
VIEWPOINTS

Brian Ingram, Director, Discovery & Translational Sciences at Metabolon Shares his Views on the Expansion of its Inflammation Portfolio

Shots: Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted Panel He also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurements The interview highlights how Metabolon’s mission to deliver…
July 6, 2023

Read more

Insights+ Key Biosimilars Events of June 2023
INSIGHTS+

Insights+ Key Biosimilars Events of June 2023

Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of June, Samsung Bioepis presented results of SB12…
July 5, 2023

Read more

VIEWPOINTS_Michael Irizarry1_2023
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study

Shots: Michael spoke about the P-III Clarity AD study evaluating Leqembi (lecanemab) for the treatment of mild cognitive impairment due to Alzheimer’s disease presented at CTAD 2022 He also talked about Eisai’s collaboration with Biogen for the co-commercialization and co-promotion of Lecanemab The interview gives an understanding of how Biogen develops and delivers innovative therapies…
July 4, 2023

Read more

Pre-Conference Interviews ISPE Singapore Conference & Exhibition 2023
EVENTS

Pre-Conference Interviews: ISPE Singapore Conference & Exhibition 2023

The ISPE Singapore Affiliate Conference & Exhibition is one of the largest and most renowned pharmaceutical manufacturing shows in Singapore for pharmaceutical and biomanufacturing professionals. The annual event highlights the best practices and services from manufacturing facility design to finished products. Click here to register now! We are thrilled to announce that we are taking the…
July 1, 2023

Read more

Top Performing Drug – Enbrel (June Edition)
INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…
June 28, 2023

Read more

VIEWPOINTS_Dr. Mourad Farouk Rezk1_2023
VIEWPOINTS

Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on Positive P-III Data for BIIB800 (Actemra biosimilar)

Shots : Dr. Mourad talked about the positive P-III data showing results for BIIB800, a Tocilizumab biosimilar candidate presented at the Annual European Congress of Rheumatology (EULAR 2022) He also spoke about the results of the 48-week analysis of the PROPER trial evaluating   adalimumab biosimilar, Imraldi, in patients with autoimmune diseases The interview highlights Biogen's…
June 27, 2023

Read more

VIEWPOINTS_Andrea Mugan_2023
VIEWPOINTS

Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign

Shots: Andrea briefed PharmaShots about the global prostate cancer awareness ‘Never Miss’ campaign developed by AstraZeneca and MSD to help men understand their potential risk of developing prostate cancer He also talked about the increasing number of prostate cancer patients and how this campaign will help support those who may be impacted by prostate cancer…
June 22, 2023

Read more

Load more